Key facts
- This page summarizes Nancy A. Simonian's Form 4 filing for Syros Pharmaceuticals, Inc. (SYRS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Nov 2024, 17:01.
Nancy A. Simonian - 31 Oct 2024 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)
- Reporting relationship
- Director
- Issuer ticker
- SYRS
- Reported as of
- 31 Oct 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Nov 2024, 17:01:59 UTC
- Prior SEC filing
- 07 Jun 2024
- Next SEC filing
- 27 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Todd Rosenthal, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Nancy A. Simonian filed Form 4 for Syros Pharmaceuticals, Inc. (SYRS) on 04 Nov 2024.
Change
- Previous filing in this sequence was filed on 07 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SYRS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +40,125
- Change %
- +30%
- Price
- Shares after
- 175,783
- Date
- 31 Oct 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SYRS
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -40,125
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 31 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,125
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents shares of common stock received upon vesting of a restricted stock unit award.
Footnote F2
Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Footnote F3
Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.